Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease

Area of Science:

• Endocrinology
• Cardiology
• Pharmacology

Background:

• Cardiovascular disease (CVD) is the leading cause of mortality in diabetic patients, surpassing acute complications.
• Diabetic CVD encompasses premature atherosclerosis, myocardial infarction, and diabetic cardiomyopathy.
• The renin-angiotensin-aldosterone system (RAAS) is critically involved in the development and progression of diabetic CVD.

Purpose of the Study:

• To outline the historical shifts in understanding the RAAS.
• To explain how diabetes mellitus alters RAAS activity.
• To identify novel RAAS pathway targets for managing diabetic CVD.

Main Methods:

• Review of historical research and paradigm shifts in RAAS understanding.
• Analysis of how diabetes impacts the RAAS.
• Exploration of emerging therapeutic targets within the RAAS pathway.

Main Results:

• Current therapies like ACE inhibitors and ARBs are first-line for CVD prevention in diabetes.
• Diabetes significantly modifies the RAAS, contributing to CVD.
• New RAAS components represent potential targets for novel therapeutic strategies.

Conclusions:

• Understanding RAAS modulation is crucial for combating diabetic CVD.
• Targeting novel aspects of the RAAS pathway offers promising avenues for future treatments.
• Continued research into RAAS modulation is essential for improving outcomes in diabetic patients with CVD.